V8 Peptides — Engineered Performance
Research Library
KPV in Inflammation Research Models: Pathways, Readouts
KPVMechanism

KPV in Inflammation Research Models: Pathways, Readouts

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

In which models has KPV been studied for inflammatory pathways? Published work uses intestinal, bronchial and keratinocyte cell lines plus mouse colitis models, with readouts that include NF-κB activity, MAP kinase signaling, cytokine secretion, myeloperoxidase and histology. Results consistently show reduced NF-κB-linked readouts in those systems; evidence outside them is absent. For laboratory research use only.

Researchers who search for KPV in inflammation models want a map: which cells have been used, which stimulus was applied and what was measured. This article is that map. It organizes the published cell and animal work by model system and by readout, so that someone planning an experiment can see where evidence exists and where it does not. It does not argue for any outcome. For laboratory research use only; not for human consumption.

KPV is the C-terminal tripeptide (Lys-Pro-Val) of α-MSH; its background is in the KPV research overview and what is KPV, and the pathway in cultured cells is dissected separately in the article on NF-κB cell-culture evidence. The KPV research vials page lists the supplied form: 5 mg and 10 mg lyophilized vials, ≥98% HPLC purity, C16H30N4O4.

Why a tripeptide became an inflammation probe

α-MSH is a tridecapeptide with anti-inflammatory effects in many models, but it also drives pigmentation, which is a nuisance if the question is about inflammation. A review of α-MSH and its related tripeptides notes that the C-terminal tripeptide KPV preserved anti-inflammatory activity while lacking pigmentary action, which is why it was singled out as a simpler molecule to study [5]. A broader pharmacology review frames melanocortin receptors as a route to controlling inflammation [7]. KPV's appeal as a research tool therefore comes from being small, easy to make and detached from classic receptor-driven pigmentation. See KPV vs α-MSH for the parent comparison.

Model systems used in the published work

Model systemStimulus reportedSource
Intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cellsPro-inflammatory cytokines[1]
Immortalised human bronchial epithelial cells (16HBE14o-)TNFα and respiratory syncytial virus[2]
HaCaT human keratinocytes (and normal keratinocytes for related peptides)TNF-α[3]
Mouse DSS and TNBS colitisChemically induced epithelial injury[1, 4]
Mouse CD45RBhi T-cell transfer colitisAdoptive transfer of naive T cells[4]

The pattern is epithelial barrier tissue: gut, airway and skin. That reflects both the biology of α-MSH, which is found in barrier organs, and the convenience of epithelial cell lines. Missing from the list are endothelial cells, primary neurons and most macrophage-based systems, so claims about those cell types would extrapolate beyond what these abstracts report.

Readouts, grouped by what they measure

A readout is only as informative as the question it answers. The published work uses at least four families, and mixing them causes confusion.

Readout familyExamples in the reportsWhat it can answerWhat it cannot
Transcription-factor activityNF-κB luciferase reporter, EMSA, p65 immunofluorescence [1, 3, 2]Whether a stimulus-driven transcriptional program was reducedWhich upstream step was blocked
Kinase pathwaysMAP kinase signaling, western blot [1]Whether a second pathway moved with NF-κBCausality between pathways
Secreted mediatorsCytokine ELISA, IL-8 and eotaxin secretion, MMP-9 activity [1, 2]Downstream output of the programCell-type source in mixed systems
Tissue readoutsHistology, myeloperoxidase activity, cytokine mRNA, survival [1, 4]Overall inflammatory burden in a modelCellular mechanism

NF-κB is the common thread. It is a family of transcription factors that controls many inflammatory genes, and its activation pathway is reviewed in detail [6]. Because it sits upstream of cytokines and adhesion molecules, a reduction in NF-κB reporter activity usually predicts reduced cytokine output, but the reverse inference, from cytokines back to NF-κB, is weaker.

What each model reported

In intestinal epithelial and T cells, nanomolar KPV reduced activation of NF-κB and MAP kinase signaling and lowered pro-inflammatory cytokine secretion, and the effect depended on PepT1-mediated uptake [1]. In bronchial epithelial cells, KPV reduced NF-κB reporter activity, matrix metalloproteinase-9 activity and secretion of IL-8 and eotaxin in a dose-dependent manner; the authors associated this with nuclear import of KPV, stabilization of IκBα and reduced nuclear translocation of p65 [2]. In HaCaT keratinocytes, KPV and an analog with D-valine each reduced TNF-α-stimulated NF-κB/p65 activation, while two ACTH peptides did not in the same cell line [3].

In vivo, KPV in DSS colitis was reported to produce earlier recovery in body-weight change, reduced inflammatory infiltrates and reduced myeloperoxidase activity, and it also reduced readouts in transfer colitis; in mice with a nonfunctional melanocortin-1 receptor, all animals in the KPV group survived DSS colitis, suggesting that the effect did not rely entirely on that receptor [4]. The models and their differences are developed in the article on murine colitis studies.

How to choose a readout for a new experiment

  1. Start from the question. If the question is whether KPV enters cells, uptake assays come first (see KPV and PepT1 uptake background). If it is whether a signaling step changes, use reporter and translocation assays. If it is a tissue-level question, an animal model is needed.
  2. Pick a stimulus that matches the cell. Cytokines for epithelial lines, virus or TNFα for airway cells, TNF-α for keratinocytes, as in the cited work.
  3. Include a time course. Transcription-factor translocation is fast; cytokine secretion lags. A single time point can miss the effect.
  4. Check viability. A reduced signal may reflect fewer living cells; a viability assay in parallel is a basic control.
  5. Use an irrelevant tripeptide as a control. It tests whether any short peptide would behave the same, though the published abstracts do not describe such a control in every case, so confirm in the full papers.

Common sources of error

Several issues affect any KPV cell experiment. Peptide counterion and net peptide content change the actual molar amount delivered, and residual trifluoroacetate from purification can itself affect cultured cells, a point developed in the article on KPV synthesis and chemistry. The reported effective concentrations are in the nanomolar range in some systems, where adsorption to plastic is proportionally significant. And because KPV is taken up through PepT1 in the gut-cell work, expression of that transporter differs between cell lines and may differ between passages, so the cell line's PepT1 status matters as much as the peptide.

The arithmetic for a stock is a formula: concentration equals mass divided by volume; molar concentration equals that figure divided by about 342.4 g/mol. The reconstitution calculator handles the sums, and the batch documentation described on the COA page shows what purity and identity have been reported.

Reading discordant results

Not every comparison in the literature points the same way, and the differences are informative. The keratinocyte work found that two ACTH peptides failed to inhibit NF-κB in HaCaT cells even though α-MSH-derived peptides did [3], which shows that peptides from the same precursor cannot be assumed interchangeable. The bronchial work found that KPV and γ-MSH reduced the same readouts by different routes, nuclear import for one and receptor activation for the other [2], so a similar readout does not imply a similar mechanism. And the colitis work found KPV effective in mice with a nonfunctional MC1R, which argues against that single receptor as the explanation [4].

When a new result differs from a published one, the first checks are cell line and passage, stimulus strength, time point, peptide identity and purity, and the form of the peptide supplied. Only after those are matched is it reasonable to suspect that biology differs. Keeping a table of those variables for every run makes later comparison possible, and it is the cheapest quality measure available to a small lab, and it costs only a few minutes per experiment.

Limits of the evidence

The cell work is mostly from a few research groups and a few epithelial lines, and the animal work is in mice. Within that scope the results are consistent in direction: reduced NF-κB-linked readouts. Beyond that scope, the evidence is silent. It does not address human tissue outside cultured lines, long exposures or interactions with other agents. For a plain statement of unknowns about the molecule, see KPV research overview; for how it compares with its parent hormone, see KPV vs α-MSH; and for how a multi-peptide product changes the design, see KLOW Stack research guide.

Frequently asked questions

In which cells has KPV been studied for inflammation signaling?

Intestinal epithelial cell lines, Jurkat T cells, immortalised bronchial epithelial cells and HaCaT keratinocytes, among others.

What is the most common readout?

NF-κB activity, measured by luciferase reporter, electrophoretic mobility shift assay or p65 localization, followed by cytokine secretion.

Did KPV affect more than NF-κB?

In the intestinal cell work, nanomolar KPV also reduced MAP kinase signaling; the studies do not establish how the two pathways are linked.

Was a receptor required?

In bronchial cells, γ-MSH required the MC3R receptor, while KPV acted through a different route involving nuclear import and p65 translocation. In mice lacking functional MC1R, KPV effects persisted.

What does PepT1 have to do with KPV?

The gut-cell work reported that KPV is transported into cells by PepT1, and that its effect depended on that uptake.

Which animal models are used?

DSS and TNBS colitis and a T-cell transfer colitis model in mice.

Why does the readout family matter?

Reporter assays, secreted mediators and tissue histology answer different questions, and conclusions drawn from one cannot be assumed for another.

What controls should accompany a KPV cell experiment?

Vehicle, viability measurement, a time course, an appropriate stimulus and, ideally, an unrelated tripeptide.

Does the evidence cover human tissue?

The cited work uses human cell lines and mouse models. It does not cover intact human tissue.

How do I prepare a stock for a cell experiment?

Concentration equals mass divided by diluent volume. Use the reconstitution calculator and record the figures on the tube.

Related reading: KPV in Murine Colitis Models: DSS, TNBS and Transfer, KPV Nanoparticle Delivery Systems: A Research Review, KPV and NF-κB Signaling: Evidence by Pathway Step.

References

  1. Dalmasso G, Charrier–Hisamuddin L, Thu Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026
  2. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2). PMID: 22837805
  3. Moustafa M, Helen Kemp E, MacNeil S, Szabo M, Haycock JW, Ghanem GE, et al. Inhibition of Tumor Necrosis Factor-α Stimulated NFκB/p65 in Human Keratinocytes by α-Melanocyte Stimulating Hormone and Adrenocorticotropic Hormone Peptides. Journal of Investigative Dermatology. 2002;119(6):1244-1253. doi:10.1046/j.1523-1747.2002.19602.x
  4. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331. doi:10.1002/ibd.20334
  5. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases. Endocrine Reviews. 2008;29(5):581-602. doi:10.1210/er.2007-0027
  6. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Sig Transduct Target Ther. 2017;2(1): doi:10.1038/sigtrans.2017.23
  7. Catania A, Gatti S, Colombo G, Lipton JM. Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation. Pharmacological Reviews. 2004;56(1):1-29. doi:10.1124/pr.56.1.1

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.